Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

NextEdge Admin

04 Feb 2025

2 min 57 sec

Exacta AI,multi-analyte system,Antibody-Drug Conjugates,Oncology,targeted therapies,Precision Medicine

Datar Cancer Genetics (DCG) has launched Exacta AI, an advanced AI-driven platform designed to provide optimized treatment options for cancer patients who have exhausted standard therapies. This next-generation multi-analyte system integrates a 360° tumor work-up with AI-assisted analysis, decoding complex tumor interactome data—including molecular (NGS: DNA+RNA), proteomic, genomic, functional, and clinical insights—to deliver personalized treatment recommendations with thorough risk-benefit analysis.

Exacta AI processes real-time wet lab data and integrates it with vast knowledge sources to assess drug synergy, interactions, toxicity, and contraindications across various treatment modalities, including Antibody-Drug Conjugates (ADCs), Checkpoint Inhibitors (CPIs), targeted therapies, endocrine agents, chemotherapy, and repurposed drugs. It can recommend up to 10 evidence-based multi-drug combinations for oncologists and molecular tumor boards (MTBs), offering hope to refractory or recurrent cancer patients.

Speaking at the Datar Advisory Board Meeting in Mumbai, Dr. Sewanti Limaye, Director of Medical and Precision Oncology at Sir HN Reliance Foundation Hospital, highlighted the AI-driven approach as a game-changer in structuring and analyzing multi-analyte data. Dr. Andy Gaya, Clinical Oncologist at Cromwell Hospital, London, called Exacta AI a paradigm shift in tumor analysis, improving therapy selection while reducing ineffective treatments.

Dr. Darshana Patil, Senior Director – Global Strategy and Medical Affairs, emphasized its role in transforming vast clinical data into actionable insights for oncologists and MTBs. Dr. Vineet Datta, Senior Director – Global Strategy and Business Development, noted its ability to function like a team of multidisciplinary experts, delivering precision-driven treatment recommendations in minutes.

In a retrospective in-silico study of 265 patients with drug-resistant cancers, Exacta AI generated 7-10 therapy options for 100% of cases, compared to conventional molecular profiling, which identified a maximum of two options for only 15% of patients. Available for seamless integration in cancer centers and hospitals, Exacta AI ensures continuous training, support, and updates.